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Abstract
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA
alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and
their associated factors have been described in some cases, almost nothing is known about the contribution of distorted
epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by
promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer,
we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant
downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1
and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is
associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
Human cells perform their complex physiological roles
having only a limited set of genes. Thus, in order to achieve
homeostasis, and at the same time respond to changing
environment and developmental stages, the presence of
precise and dynamic mechanisms of gene regulation is
required. Among these, alternative splicing allows the
generation of discretely different proteins encoded by the
same gene [1, 2]. It is now accepted that the vast majority of
human genes undergo some form of alternative splicing [3]
and that the thousands of generated protein isoforms overall
exert particular activities that are critical for the cellular
function. Therefore, the formation of protein diversity is
often associated with the distinct skipping or inclusion of
exons and other DNA sequences. RNA splicing is thus a
highly regulated process that relies on both in trans-reg-
ulatory factors and cis-regulatory elements. The spliceo-
some, the core macromolecular machinery that organizes
intron removal and exon junction, and its associated factors
includes more than 300 proteins and five small nuclear
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ribonucleotide particles [4]. The described balanced splicing
scenario of the normal cell and tissue becomes highly dis-
torted in cancer. Beyond particular splicing defects of spe-
cific genes associated with mutations in skipping sites for
those DNA sequences, the overall transcriptome of human
tumors exhibits global splicing abnormalities detectable by
whole transcriptome analyses [5–7], including inefficient
exon removal or inclusion of unexpected exons, associated
with protein isoforms that contribute to the transforming
phenotype [5, 7]. In this regard, an increasing number of
cancer-linked mutations in genes encoding spliceosomal
proteins and associated RNA splicing factors have recently
been reported [7–9]. However, although on many occasions
there is loss of expression of these splicing factors in the
absence of any genetic defect, the role of epigenetic lesions
targeting splicing in cancer cells have not been addressed.
Herein, we have interrogated the presence of cancer-
specific defects in the CELF protein family (CUGBP and
ETR-3-like factors), a family of RNA-binding proteins that act
as trans-acting factors enhancing or inhibiting exon inclusion
into the final messenger RNA (mRNA) [10–12]. The CELF
family consists of six members (CELF1–6) that are all char-
acterized by three RNA recognition motifs, two N terminal
and one C terminal with a linker region between them termed
the “divergent domain” that is the one involved in alternative
splicing [10–12]. To uncover candidate genetic and epigenetic
changes in the CELF family in human tumors, we first data-
mined a collection of more than 1000 human cancer cell lines
in which we have characterized the exome sequence, gene
copy number, transcriptome, and DNA methylation profiles
[13]. The available genomic data did not identify the presence
of CELF1–6 mutations or copy number changes in the studied
cell lines (Dataset S1). Although no genetic lesions were
observed in the interrogated genes, promoter CpG island
hypermethylation and its associated transcriptional silencing is
another relevant mechanism of gene inactivation in cancer
cells [14–16]. The promoter-associated CpG islands of
CELF1, CELF3, CELF4, CELF5, and CELF6 were mostly
unmethylated in the assessed cancer cell lines (Dataset S1).
However, a CELF2 promoter CpG island was commonly
methylated among different cancer cell lines types, including
pancreatic (74%, 20 of 27), gastric (57%, 16 of 28), and breast
(46%, 19 of 41) tumors (Fig. 1a and Dataset S1). The fre-
quency of promoter CpG island methylation status for the six
members of the CELF family in the studied breast cancer cell
lines is shown in Supplementary Fig. S1. The CELF2
methylated sites occurred in the CpG island located around the
transcription start site of the longest isoform of CELF2
(CELF2-TV2, GRCh37/hg19, NM_006561, originating a
55.7 kDa protein) (Dataset S1). This genomic locus was found
unmethylated in all the different normal tissue samples ana-
lyzed from the The Cancer Genome Atlas (TCGA) dataset (n
= 730) (Dataset S2), including 98 normal breast tissues. Thus,
the cancer-specific DNA methylation event at the CELF2
promoter became our focus of interest and was herein further
studied in the context of breast cancer.
Having found the CELF CpG island methylation patterns
shown above, we assessed in detail the possible association
with the loss of the CELF2 gene expression at the RNA and
protein levels. We developed bisulfite genomic sequencing
of multiple clones in the breast cancer cell lines MCF7,
MDA-MB-453, MDA-MB-231, and MDA-MB-436 using
primers that encompassed the transcription start site-linked
CpG island (Supplementary Methods). We observed that the
5′ end CpG island of CELF2 in the MCF7 and MDA-MB-
453 cell lines was hypermethylated in comparison with
normal tissues (Fig. 1b), whereas the MDA-MB-231 and
MDA-MB-436 cells were unmethylated (Fig. 1b). These data
were identical to the DNA methylation profiles obtained by
the microarray approach (Fig. 1c). The methylated CELF2
cell lines MCF7 and MDA-MB-453 minimally expressed the
CELF2-TV2 RNA transcript and the CELF2 55.7 kDa pro-
tein, as determined by quantitative real-time PCR (RT-PCR)
and western blot, respectively (Fig. 1d). Expression of
CELF2 RNA and protein was found in the unmethylated cell
lines (Fig. 1d). Treatment of the CELF2-hypermethylated
cell lines with the DNA-demethylating agent 5′-aza-2′-
deoxycytidine restored CELF2 expression (Fig. 1e). Overall,
these results indicate the presence of cancer-specific pro-
moter CpG island hypermethylation-associated loss of the
CELF2 gene. Although we have herein focused in breast
cancer, we found that epigenetic silencing of CELF2 also
occurred in pancreatic cancer cell lines and primary tumors
(Supplementary Fig. S2) and thus these results merit further
exploration in future research efforts.
Once we had demonstrated the existence of CELF2 CpG
island hypermethylation-linked transcriptional inactivation
in human breast cancer cell lines, we studied its contribution
to the tumorigenic phenotype in vitro and in vivo. Upon
efficient transduction-mediated restoration of CELF2 RNA
and protein in hypermethylated MCF7 breast cancer cells
(Fig. 2a), we tested the potential growth-inhibitory capacity
of these cells using the colony formation assay. We
observed that the recovery of CELF2 expression by trans-
duction in the MCF7 breast cancer cell line induces a sig-
nificant decrease in colony formation (Fig. 2b). We also
translated these findings to an in vivo mouse model where
we tested the ability of these CELF2-transduced MCF7 cells
to form orthotopic tumors in the mammary fat pad of nude
mice compared with empty vector-transduced cells. The
recovery of CELF2 expression in these breast tumors
diminished their growth in comparison with empty vector-
derived tumors, as observed by the continuous measurement
of the tumor volume (Fig. 2c). Tumor samples obtained at
the endpoint of the experimental model showed that tumors
derived from CELF2-transduced cells weighed less than
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those tumors obtained from empty vector-transduced cells
(Fig. 2c). Thus, our findings suggest that CELF2 has tumor
suppressor-like features in transformed cells.
We then wondered about the molecular pathways
involved in the growth-inhibitory role of CELF2. In this
regard, it is likely that, due to the recognized role of CELF2
in mRNA splicing [10–12], the epigenetic loss of CELF2 in
breast cancer cells generates a downstream aberrant splicing
pattern that contribute to the biology of these tumors. To
assess this hypothesis, we performed RNA-sequencing
(RNA-seq) to study the transcriptome in empty vector-
transduced MCF7 cells (showing CELF2 DNA
methylation-associated loss) compared with stably CELF2-
transduced MCF7 cells to characterize mRNAs whose
different transcript isoforms were CELF2-dependent (Fig.
2d). The RNA-seq data have been deposited in the
Sequence Read Archive repository (https://trace.ncbi.nlm.
nih.gov/Traces/sra/), under the SRA study ID:
PRJNA510082.
We identified 82 events of differential splicing, reflecting
distinct exon/intron usage, upon CELF2 transduction in
MCF7 cells (Table S1). Most of the CELF2 splicing targeted
RNA transcripts corresponded to messenger RNAs (mRNAs)
(71 of 82), whereas (11 of 82) were non-coding RNAs (such
as pseudogenes and antisense transcripts). Most RNAs (68%;
56 of 82) showed differences in intron retention upon the
restoration of CELF2 expression, followed by changes in






















































































Breast Cancer Cell Lines 
Unmethylated Methylated 
Normal Breast  
Target_ID Location NB1 NB2 NB3 NB4 NB5 NB6 NB7 NB8 NB9 NB10 NB11 NB12
cg10297491 Body; TSS1500 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1 0,0 0,1 0,0
cg27041794 Body; TSS200 0,0 0,1 0,1 0,1 0,0 0,0 0,1 0,1 0,1 0,1 0,1 0,1
cg17290701 Body; TSS200 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg26328510 Body; TSS200 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg03813164 Body; TSS200 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg12356890 Body; TSS200 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg11472279 Body; TSS200 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg11002404 5UTR; 1stExon; Body 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
cg04088969 5UTR; 1stExon; Body 0,0 0,0 0,1 0,0 0,1 0,0 0,0 0,0 0,1 0,1 0,1 0,1
cg25560333 1stExon; Body 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
Target_ID Location MDA-MB-231 MDA-MB-436 MCF7 MDA-MB-453
cg10297491 Body; TSS1500 0,0 0,2 0,9 1,0
cg27041794 Body; TSS200 0,1 0,1 0,8 0,9
cg17290701 Body; TSS200 0,0 0,1 0,9 0,9
cg26328510 Body; TSS200 0,0 0,1 1,0 1,0
cg03813164 Body; TSS200 0,0 0,0 1,0 1,0
cg12356890 Body; TSS200 0,0 0,0 1,0 1,0
cg11472279 Body; TSS200 0,0 0,0 1,0 1,0
cg11002404 5UTR; 1stExon; Body 0,0 0,0 1,0 1,0
cg04088969 5UTR; 1stExon; Body 0,1 0,1 0,9 0,9
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Fig. 1 CELF2 (CUGBP and ETR-3- like factor 2) promoter CpG
island hypermethylation-associated transcriptional silencing in human
cancer cells. a Percentage of CELF2 methylation in the Sanger set of
cancer cell lines according to tumor type. b Bisulfite genomic
sequencing of the CELF2 promoter CpG island in breast cancer cell
lines and normal breast tissue. CpG dinucleotides are represented as
short vertical lines; the transcription start site (TSS) is represented as a
long black arrow. Single clones are shown for each sample. The
presence of an unmethylated or methylated cytosine is indicated by a
white or black square, respectively. c DNA methylation profile of the
CELF2 promoter CpG island interrogated using the 450K DNA
methylation microarray. Single CpG absolute methylation levels (0–1)
are shown. Green, unmethylated; red, methylated. Data from the four
breast cancer cell lines and 12 normal breast samples are shown. d
Expression levels of CELF2 in breast cancer cell lines determined by
real-time PCR (data shown represent mean ± SD of biological tripli-
cates) (left) and western blot (right). e Expression of the CELF2 RNA
transcript (data shown represent the mean ± SD of biological tripli-
cates) was restored in the CELF2 hypermethylated and silenced MCF7
and MDA-MB-453 cells upon use of the inhibitor of DNA methylation
5-aza-2′-deoxycytidine (AZA). *p < 0.05, **p < 0.01, and ***p <
0.001
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affected alternative 5′-end or 3′-end splicing sites (5%, 4 of 82
and 1%, 1 of 82, respectively) (Fig. 2d). In order to better
characterize the described set of 82 RNAs with significantly
differential splicing in CELF2-transduced MCF7 cells in
comparison to empty vector-transduced cells, we performed a
gene functional annotation by computing overlaps between
our gene list and MSigDB (Molecular Signatures Database)
gene set collections. We observed an over-representation of
biological processes related to proliferation and phosphor-
ylation (FDR < 0.05 in a hypergeometric test). The top
10 significant GO categories by gene count are shown in Fig.
2e. Among the set of transcripts derived from the RNA-seq
experiment that showed different exon usage upon CELF2
recovery, and thus candidate targets of the alternative splicing
activity of the protein, we found many genes with known
oncogenic or antitumoral activities, such as the autophagy
factor ULK1 (unc-51 like autophagy activating kinase 1) [17],
the apoptotic protein CARD10 (caspase recruitment domain
family member 10) [18], the activator of EGFR signaling
RHBDF2 (rhomboid 5 homolog 2) [19], the PTEN compe-
titor FBXL2 (F-box and leucine-rich repeat protein 2) [20],
and the metastasis breast antigen NPTN (neuroplastin) [21]
(Table S1).
Fig. 2 CELF2 (CUGBP and ETR-3-like factor 2) tumor growth-
inhibitory properties and its impact in alternative splicing patterns. a
Efficient recovery of CELF2 expression upon transduction in MCF7
cells according to quantitative real-time-PCR (qRT-PCR) (left) and
western blot (right). Triplicate qRT-PCR values were analyzed and
expressed as the mean ± SD. b The colony formation assay showed
that MCF7 cells stably transduced with CELF2 formed significantly
fewer colonies than empty vector-transduced cells. Data shown
represent mean ± SD of biological triplicates. P values are those cor-
responding to Student’s t test. c Empty vector (EV) and CELF2-
transduced MCF7 cells were injected in the mammary fat pad of nude
mice to form orthotopic tumors. Tumor volume over time (left) and
tumor weight upon sacrifice (right) are shown. P values are those
corresponding to Student’s t test. Bars show means ± SD. d Workflow
of the RNA-sequencing (RNA-seq) analysis developed to detect RNA
alternative splicing changes in MCF7 cells upon CELF2 transduction.
e Gene ontology analysis (GO) of the RNAs with differential splicing
in MCF7 cells upon CELF2 transduction (hypergeometric test with a
false discovery rate (FDR) adjusted p value < 0.05). f Validation of
CELF2 splicing targets in breast cancer cells. Restoration of CELF2
expression by transduction in CELF2 hypermethylated MCF7 cells
induces a shift in the splicing patterns of NPTN, ULK1, CARD10,
RHBDF2, and FBXL2, determined by exon-specific qRT-PCR. P
values are those corresponding to Student’s t test. Bars show means ±
SD. *p < 0.05, **p < 0.01, and ***p < 0.001
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The identification of these transcripts in our RNA-seq
approach, which can likely contribute to breast tumorigen-
esis, motivated us to further validate the role of CELF2
epigenetic loss in their proposed dysregulated alternative
splicing. In this regard, we confirmed by exon-specific
quantitative RT-PCR (Supplementary Methods) that the
restoration of CELF2 expression in MCF7 cells sig-
nificantly enriched intron 12 retention for FBXL2, whereas
retention of the intron 17 for ULK1 and CARD10, retention
of the intron 2 for RHBDF2, and exon 2 skipping in NPTN
were diminished upon transduction-mediated recovery of
CELF2 (Fig. 2f). These were the same splicing events
detected in our “omics” strategy (Fig. 2d) for these genes
(Table S1). We also developed a second model of recovery
of CELF2 expression in addition to MCF7. Using the
MDA-MB-453 cell line, originally harboring DNA
methylation-associated CELF2 silencing (Fig. 1), we per-
formed transduction-mediated recovery of CELF2 expres-
sion. (Supplementary Fig. S3). We observed that the intron
retention splicing patterns of CELF2-transduced MDA-MB-
453 cells (Supplementary Fig. S3) mimicked those observed
in CELF2-transduced MCF7 cells (Fig. 2f). We also vali-
dated the CELF2-transduced MCF7 in vivo tumor growth
data in the new CELF2-transduced MDA-MB-453 model,
where the recovery of CELF2 expression inhibited tumor
growth (Supplementary Fig. S3). We also created the
opposite model by obtaining a stably CELF2-depleted cell
line. In this regard, we used the breast cancer cell line
DU4475, unmethylated for the CELF2 promoter and
expressing its transcript and protein (Supplementary Fig. S4),
Age (< vs > 60 years)
Subtypes (luminal vs non-luminal)
Her2 status (positive vs negative) 
CELF2 hypermethylation
0.99 (0.71 – 1.37); p = 0.93
1.05 (0.84 – 1.31); p = 0.65
1.47 (0.59 – 3.70); p = 0.41 
1.40 (1.02 – 1.93); p = 0.04*
HR (95% CI)Patients features (N= 423)
1 20.50
HR for CSS  (95% CI)
5
49.0 = p ;)47.1– 55.0( 79.0 )evitagen sv evitisop( sutats RP/RE
CSS: cancer specific survival; ER/PR: estrogen/progesterone receptors; HR: Hazard Ratio; 95%
CI: 95% of confidence interval;
RiskBenefit
Unmethylated
(n = 280)  
Methylated
(n = 143)  
Log Rank; p-value = 0.015















CELF2 methylation effect on
CELF2 expression
Methylation of CELF2 in primary tumors from TCGA
2FLEC:ksir tA
280 233 204 190 184 184 U



































































































































































































Fig. 3 CELF2 (CUGBP and ETR-3-like factor 2) promoter hyper-
methylation in human breast cancer is associated with poor clinical
outcome. a Percentage of CELF2 methylation in the The Cancer
Genome Atlas (TCGA) dataset of primary tumors according to tumor
type. b CELF2 promoter CpG island methylation is associated with the
loss of the CELF2 transcript in primary breast tumors from the TCGA
dataset. c Kaplan–Meier analysis of cancer-specific survival in 423
primary breast tumors according to CELF2 methylation status deter-
mined by pyrosequencing. The p value corresponds to the log-rank
test. Results of the univariate Cox regression analysis are represented
by the hazard ratio (HR) and 95% confidence interval (CI). CELF2
hypermethylation is associated with shorter cancer-free survival. d
Multivariate Cox regression analysis of cancer-specific survival,
represented by a forest plot, taking into account the clinical char-
acteristics of the cohort of breast cancer patients. Values of p < 0.05
were considered statistically significant. In multivariate analyses, sig-
nificant covariates are considered independent prognostic factors of
clinical outcome; as it occurred for CELF2 hypermethylation. *p <
0.05, ***p < 0.001
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where we obtained by the short hairpin RNA (shRNA)
approach a cell line with depleted levels of the CELF2
transcript and protein (Supplementary Fig. S4). We
observed that the induced loss of CELF2 completely
reversed the differential intron retention patterns of the
target genes (Supplementary Fig. S4) in comparison to the
restoration of CELF2 activity in MCF7 (Fig. 2f) or MDA-
MB-453 (Supplementary Fig. S3) cells. To further demon-
strate the contribution of the differential splicing events
mediated by CELF2 loss to breast cancer, we studied one
case in detail. Based on our observation that exon 2 reten-
tion in NPTN was increased upon transduction-mediated
recovery of CELF2 in hypermethylated MCF7 cells (Fig.
2f), we specifically depleted by shRNA the exon 2 retained
isoform of NPTN in these CELF2 stably transduced cells
(Supplementary Fig. S5). We found that this intervention
reversed the observed CELF2-mediated growth inhibition
phenotype (Fig. 2b), inducing now an increase in colony
formation (Supplementary Fig. S5). Overall, these data
support that the identified genes are bona fide targets of
CELF2-mediated alternative splicing and that the epigenetic
loss of this last factor in breast cancer is associated with
their imbalanced isoform content in transformed cells.
Finally, we demonstrated that CELF2 hypermethylation-
associated silencing was not exclusively an in vitro cell
phenomenon by translating our observations to human pri-
mary tumors. Data mining of the human primary tumor
collection of TCGA project (https://cancergenome.nih.gov/),
studied by the same DNA methylation microarray used
herein [22], demonstrated the presence of CELF2 CpG
island hypermethylation in a wide spectrum of tumor types
(Fig. 3a) that resembled the one described in the cancer cell
line cohort (Fig. 1a). Due to our interest and models for
CELF2 in breast cancer, we further studied this tumor type
in the primary context, observing that the CpG island
methylation of CELF2 was found in 39% (263 of 679) of
primary breast tumors included in the TCGA dataset (Fig.
3a). Using the available RNA-seq data from the TCGA in
breast cancer, we observed that CELF2 CpG island promoter
hypermethylation was associated with downregulation of its
transcript (Fig. 3b). The link between CELF2 hypermethy-
lation and gene inactivation was further strengthened by
data-mining confirmation in early and late passages of PDXs
established from human primary breast tumors [23] of the
association of CELF2 promoter methylation with the loss of
the corresponding transcript (Supplementary Fig. S6). Fur-
thermore, data-mining DNA methylation microarray data
available for ductal carcinoma in situ (DCIS) samples [24],
we observed that CELF2 hypermethylation occurred early in
breast tumorigenesis, and was already present in 11 of 40
(28%) DCIS cases (Supplementary Fig. S7).
We then wondered whether CELF2 methylation was of
any prognostic value with respect to the growth-inhibitory
capacity observed in the in vitro (Fig. 2b) and in vivo (Fig.
2c) models upon CELF2 restoration. To analyze this issue,
we studied a cohort of 423 primary breast tumors in which
we assessed the CELF2 methylation status by pyr-
osequencing (Supplementary Methods). We found CELF2
CpG island hypermethylation in 34% (143 of 423) of the
primary breast tumor cases, in line with the observed fre-
quency in the TCGA dataset (39%) (Fig. 3a). CELF2
methylation status was associated with other clinical vari-
ables and biomarkers such as younger age (Fisher’s exact
test p < 0.001), the luminal subtype (χ2 test p= 0.007) and
positivity for estrogen receptor/progesterone receptor (ER/
PR) status (χ2 test p= 0.018) (Table S2). Importantly, these
clinicopathological parameters were also significantly
associated between them (younger age/ER/PR positivity, χ2
test p < 0.001; luminal type/ER/PR positivity, χ2 test p <
0.001) (Table S2). Most relevant, the presence of the
CELF2 epigenetic alteration was associated with shorter
cancer-specific survival (log-rank; p= 0.015; hazard ratio
(HR)= 1.48, confidence interval (95% CI)= 1.08–2.04)
(Fig. 3c). These observations indicate that the epigenetic
loss of the splicing factor CELF2 constitutes a candidate
prognostic marker of poor clinical outcome in breast cancer
patients. Furthermore, multivariate Cox regression analysis
showed that CELF2 hypermethylation was an independent
predictor of shorter cancer-specific survival in breast cancer
(HR= 1.40, p= 0.04; 95% CI= 1.02–1.93), in comparison
to all other patient characteristics (Fig. 3d).
Overall, our data indicate that CELF2, a RNA-binding
protein involved in alternative splicing, undergoes promoter
CpG island hypermethylation-associated transcriptional
silencing in human tumors where we have herein particu-
larly focused on the case of breast cancer. From a
mechanistic standpoint, the epigenetic loss of CELF2 is
associated with an altered downstream pattern of exon
usage in a set of target genes. Most importantly from a
cellular and clinical view, the epigenetic loss of CELF2
enhances the growth of breast tumors, and it is associated
with those breast cancer patients with the worst outcomes.
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